India to Turkey: Trastuzumab Export Trade Route

The India to Turkey Trastuzumab corridor is one of India's established pharmaceutical export routes, with 54 shipments documented worth a combined $10.2M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 99% of all export value, reflecting the consolidated nature of India's trastuzumab manufacturing sector.

Across 9 active suppliers, the average shipment value stands at $188.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 79% of all shipments, consistent with trastuzumab's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 26 days port-to-port. The route has recorded an annual growth rate of 17.4%, placing it at rank #11 among India's top trastuzumab export destinations globally.

On the import side, key buyers of Indian trastuzumab in Turkey include ABDI IBRAHIM ILAC SANAYI VE TICARET, ABDI IBRAHIM ILAC SANAYI VE TICARET SANAYIMAH TUNC, AL HASEM OTOMOTIV TICARET LIMITED S and 9 others. ABDI IBRAHIM ILAC SANAYI VE TICARET is the single largest importer with 22 shipments valued at $8.2M USD.

India's trastuzumab exports to Turkey are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 28 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 9 active exporters signals a competitive but concentrated market — buyers in Turkey benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, RAWIA INTERNATIONAL HEALTHCARE PRIVATE LIMITED, RMPL PHARMA LLP — together account for 100% of total trade value on this route. The average shipment value of $188.0K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as canhera-150- trastuzumab-1s-turkey b/n 7802307 and canhera-150- trastuzumab-1s-turkey b/n 7802325, suggesting that buyers in Turkey tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, ABDI IBRAHIM ILAC SANAYI VE TICARET is the largest importer with 22 shipments worth $8.2M USD — representing 80% of all trastuzumab imports from India on this route. A total of 12 buyers are active on this corridor.